Quantitative Evaluation of Dendritic Nanoparticles in Mice: Biodistribution Dynamics and Downstream Tumor Efficacy Outcomes

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Quantitative Evaluation of Dendritic Nanoparticles in Mice : Biodistribution Dynamics and Downstream Tumor Efficacy Outcomes. / Vasalou, Christina; Ferguson, Douglas; Li, Weimin; Muse, Victorine; Gibbons, Francis D.; Sonzini, Silvia; Zhang, Guangnong; Pop-Damkov, Petar; Gangl, Eric; Balachander, Srividya B.; Wen, Shenghua; Schuller, Alwin G.; Puri, Sanyogitta; Mazza, Mariarosa; Ashford, Marianne; Fretland, Adrian J.; McGinnity, Dermot F.; Jones, Rhys D. O.

In: Molecular Pharmaceutics, Vol. 19, No. 1, 2022, p. 172-187.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Vasalou, C, Ferguson, D, Li, W, Muse, V, Gibbons, FD, Sonzini, S, Zhang, G, Pop-Damkov, P, Gangl, E, Balachander, SB, Wen, S, Schuller, AG, Puri, S, Mazza, M, Ashford, M, Fretland, AJ, McGinnity, DF & Jones, RDO 2022, 'Quantitative Evaluation of Dendritic Nanoparticles in Mice: Biodistribution Dynamics and Downstream Tumor Efficacy Outcomes', Molecular Pharmaceutics, vol. 19, no. 1, pp. 172-187. https://doi.org/10.1021/acs.molpharmaceut.1c00715

APA

Vasalou, C., Ferguson, D., Li, W., Muse, V., Gibbons, F. D., Sonzini, S., Zhang, G., Pop-Damkov, P., Gangl, E., Balachander, S. B., Wen, S., Schuller, A. G., Puri, S., Mazza, M., Ashford, M., Fretland, A. J., McGinnity, D. F., & Jones, R. D. O. (2022). Quantitative Evaluation of Dendritic Nanoparticles in Mice: Biodistribution Dynamics and Downstream Tumor Efficacy Outcomes. Molecular Pharmaceutics, 19(1), 172-187. https://doi.org/10.1021/acs.molpharmaceut.1c00715

Vancouver

Vasalou C, Ferguson D, Li W, Muse V, Gibbons FD, Sonzini S et al. Quantitative Evaluation of Dendritic Nanoparticles in Mice: Biodistribution Dynamics and Downstream Tumor Efficacy Outcomes. Molecular Pharmaceutics. 2022;19(1):172-187. https://doi.org/10.1021/acs.molpharmaceut.1c00715

Author

Vasalou, Christina ; Ferguson, Douglas ; Li, Weimin ; Muse, Victorine ; Gibbons, Francis D. ; Sonzini, Silvia ; Zhang, Guangnong ; Pop-Damkov, Petar ; Gangl, Eric ; Balachander, Srividya B. ; Wen, Shenghua ; Schuller, Alwin G. ; Puri, Sanyogitta ; Mazza, Mariarosa ; Ashford, Marianne ; Fretland, Adrian J. ; McGinnity, Dermot F. ; Jones, Rhys D. O. / Quantitative Evaluation of Dendritic Nanoparticles in Mice : Biodistribution Dynamics and Downstream Tumor Efficacy Outcomes. In: Molecular Pharmaceutics. 2022 ; Vol. 19, No. 1. pp. 172-187.

Bibtex

@article{cd06767de6244ed5a9eee2fdcebd18af,
title = "Quantitative Evaluation of Dendritic Nanoparticles in Mice: Biodistribution Dynamics and Downstream Tumor Efficacy Outcomes",
abstract = "A physiologically based pharmacokinetic model was developed to describe the tissue distribution kinetics of a dendritic nanoparticle and its conjugated active pharmaceutical ingredient (API) in plasma, liver, spleen, and tumors. Tumor growth data from MV-4-11 tumor-bearing mice were incorporated to investigate the exposure/efficacy relationship. The nanoparticle demonstrated improved antitumor activity compared to the conventional API formulation, owing to the extended released API concentrations at the site of action. Model simulations further enabled the identification of critical parameters that influence API exposure in tumors and downstream efficacy outcomes upon nanoparticle administration. The model was utilized to explore a range of dosing schedules and their effect on tumor growth kinetics, demonstrating the improved antitumor activity of nanoparticles with less frequent dosing compared to the same dose of naked APIs in conventional formulations.",
keywords = "nanoparticles, dendrimers, biodistribution, modeling and simulation, tumor growth kinetics",
author = "Christina Vasalou and Douglas Ferguson and Weimin Li and Victorine Muse and Gibbons, {Francis D.} and Silvia Sonzini and Guangnong Zhang and Petar Pop-Damkov and Eric Gangl and Balachander, {Srividya B.} and Shenghua Wen and Schuller, {Alwin G.} and Sanyogitta Puri and Mariarosa Mazza and Marianne Ashford and Fretland, {Adrian J.} and McGinnity, {Dermot F.} and Jones, {Rhys D. O.}",
year = "2022",
doi = "10.1021/acs.molpharmaceut.1c00715",
language = "English",
volume = "19",
pages = "172--187",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "1",

}

RIS

TY - JOUR

T1 - Quantitative Evaluation of Dendritic Nanoparticles in Mice

T2 - Biodistribution Dynamics and Downstream Tumor Efficacy Outcomes

AU - Vasalou, Christina

AU - Ferguson, Douglas

AU - Li, Weimin

AU - Muse, Victorine

AU - Gibbons, Francis D.

AU - Sonzini, Silvia

AU - Zhang, Guangnong

AU - Pop-Damkov, Petar

AU - Gangl, Eric

AU - Balachander, Srividya B.

AU - Wen, Shenghua

AU - Schuller, Alwin G.

AU - Puri, Sanyogitta

AU - Mazza, Mariarosa

AU - Ashford, Marianne

AU - Fretland, Adrian J.

AU - McGinnity, Dermot F.

AU - Jones, Rhys D. O.

PY - 2022

Y1 - 2022

N2 - A physiologically based pharmacokinetic model was developed to describe the tissue distribution kinetics of a dendritic nanoparticle and its conjugated active pharmaceutical ingredient (API) in plasma, liver, spleen, and tumors. Tumor growth data from MV-4-11 tumor-bearing mice were incorporated to investigate the exposure/efficacy relationship. The nanoparticle demonstrated improved antitumor activity compared to the conventional API formulation, owing to the extended released API concentrations at the site of action. Model simulations further enabled the identification of critical parameters that influence API exposure in tumors and downstream efficacy outcomes upon nanoparticle administration. The model was utilized to explore a range of dosing schedules and their effect on tumor growth kinetics, demonstrating the improved antitumor activity of nanoparticles with less frequent dosing compared to the same dose of naked APIs in conventional formulations.

AB - A physiologically based pharmacokinetic model was developed to describe the tissue distribution kinetics of a dendritic nanoparticle and its conjugated active pharmaceutical ingredient (API) in plasma, liver, spleen, and tumors. Tumor growth data from MV-4-11 tumor-bearing mice were incorporated to investigate the exposure/efficacy relationship. The nanoparticle demonstrated improved antitumor activity compared to the conventional API formulation, owing to the extended released API concentrations at the site of action. Model simulations further enabled the identification of critical parameters that influence API exposure in tumors and downstream efficacy outcomes upon nanoparticle administration. The model was utilized to explore a range of dosing schedules and their effect on tumor growth kinetics, demonstrating the improved antitumor activity of nanoparticles with less frequent dosing compared to the same dose of naked APIs in conventional formulations.

KW - nanoparticles

KW - dendrimers

KW - biodistribution

KW - modeling and simulation

KW - tumor growth kinetics

U2 - 10.1021/acs.molpharmaceut.1c00715

DO - 10.1021/acs.molpharmaceut.1c00715

M3 - Journal article

C2 - 34890209

VL - 19

SP - 172

EP - 187

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 1

ER -

ID: 288114045